Prevalence and severity of menopausal symptoms in women over 60 years of age
PDF (Español (España))


Signs and symptoms
Risk factors
quality of life

How to Cite

Espitia de la Hoz, F. . (2024). Prevalence and severity of menopausal symptoms in women over 60 years of age. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 11(1).


Background: The symptoms of menopause can be as severe or prolonged over time, with the possibility of affecting the quality of life of women who suffer from them.

Purpose: to determine the prevalence and severity of menopause symptoms in women aged 60 or older, and to know the associated risk factors.

Methodology: cross-sectional study in 117 women aged 60 or older with an intact uterus and menopausal symptoms, residing in Quindío, Colombia; between 2017 and 2023. Quality of life was evaluated with the Menopause Rating Scale (MRS) instrument. A descriptive analysis was done.

Results: the average age of the women was 67.53 ± 8.24 years; in the total number of participants; the prevalence of menopause symptoms was 9.87%, with hot flashes predominating (80.34%). In the MRS scale, the urogenital domain reported the greatest impact on the severity of the symptoms (average: 8.94 ± 2.07 points); Vaginal dryness was the most common complaint (58.97%). The associated factors highlight early menopause (OR: 3.87; 95% CI: 1.81 - 8.33) and smoking (OR: 2.97; 95% CI: 1.44 - 6.31). Greater education (OR: 0.34; 95% CI: 0.16 - 0.91) was shown to be a protective factor. 27.35% of the total participants scored ?16 (severe) in the intensity of the symptoms according to the MRS scale, compatible with the need for treatment. Work efficiency was severely affected in 20.51% of women followed by household responsibilities with 15.38%.

Conclusions: the symptoms of menopause can be present in women aged 60 or older, being described by a tenth of the residents of the department of Quindío.
PDF (Español (España))


Espitia-De La Hoz FJ. Prevalencia y caracterización de los síntomas de la menopausia en mujeres climatéricas del Eje Cafetero (Colombia), 2018-2020. Univ Med. 2022;63(3).

Santoro N, Roeca C, Peters BA, Neal-Perry G. The menopause transition: signs, symptoms, and management options. J Clin Endocrinol Metab. 2021 en. 1;106(1):1-15.

Hill K. The demography of menopause. Maturitas. 1996 mzo.;23(2):113-27.

Davis SR, Pinkerton J, Santoro N, Simoncini T. Menopause-biology, consequences, supportive care, and therapeutic options. Cell. 2023 sept. 14;186(19):4038-58.

Baber RJ, Panay N, Fenton A. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016 abr.;19(2):109-50.

Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, et al. Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015 nov.;100(11):3975-4011.

Nappi RE, Kroll R, Siddiqui E, Stoykova B, Rea C, Gemmen E, et al. Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden. Menopause. 2021 my. 24;28(8):875-82.

Crawford SL. For vasomotor symptoms, timing-and duration-may be everything. Menopause. 2014 sept.;21(9):917-9.

Richard-Davis G, Manson JE. Vasomotor symptom duration in midlife women-research overturns dogma. JAMA Intern Med. 2015 abr.;175(4):540-1.

Dennerstein L, Lehert P, Burger HG, Guthrie JR. New findings from non-linear longitudinal modelling of menopausal hormone changes. Hum Reprod Update. 2007;13(6):551-7.

Freeman EW, Sammel MD, Lin H, Gracia CR, Pien GW, Nelson DB, et al. Symptoms associated with menopausal transition and reproductive hormones in midlife women. Obstet Gynecol. 2007 ag.;110(2 Pt 1):230-40.

Nelson HD. Menopause. Lancet. 2008 mzo. 1;371(9614):760-70.

Palacios S, Henderson VW, Siseles N, Tan D, Villaseca P. Age of menopause and impact of climacteric symptoms by geographical region. Climacteric. 2010 oct.;13(5):419-28.

Gartoulla P, Worsley R, Bell RJ, Davis SR. Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years. Menopause. 2015 jul.;22(7):694-701.

Zeleke BM, Bell RJ, Billah B, Davis SR. Vasomotor and sexual symptoms in older Australian women: a cross-sectional study. Fertil Steril. 2016 en.;105(1):149-55.e1.

Mishra GD, Pandeya N, Dobson AJ, Chung HF, Anderson D, Kuh D, et al. Early menarche, nulliparity and the risk for premature and early natural menopause. Hum Reprod. 2017 mzo. 1;32(3):679-86.

Espitia de la Hoz FJ, Orozco Gallego H. Abordaje diagnóstico y terapéutico del síndrome genitourinario en la menopausia; Actualización. Rev Méd Universidad de Costa Rica.2018;11(2):67-84.

Marino JM. Genitourinary syndrome of menopause. J Midwifery Womens Health. 2021 nov.;66(6):729-39.

Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004 oct. 18;2004(4):CD002978.

Hauser GA, Huber IC, Keller PJ, Lauritzen C, Schneider HP. [Evaluation of climacteric symptoms (Menopause Rating Scale)]. Zentralbl Gynakol. 1994;116(1):16-23.

Heinemann LA, Potthoff P, Schneider HP. International versions of the Menopause Rating Scale (MRS). Health Qual Life Outcomes. 2003 jul. 30;1:28.

Heinemann K, Ruebig A, Potthoff P, Schneider HP, Strelow F, Heinemann LA, et al. The Menopause Rating Scale (MRS) scale: a methodological review. Health Qual Life Outcomes. 2004;2:45.

Metintas S, Arýkan I, Kalyoncu C, Ozalp S. Menopause Rating Scale as a screening tool in rural Turkey. Rural Remote Health. 2010;10(1):1230.

Xueyin W, Linhong W, Jiangli D, Xiaosong Z, Gengli Z. Prevalence and risk factors for menopausal symptoms in middle-aged Chinese women: a community-based cross-sectional study. Menopause. 2021 ag. 30;28(11):1271-8.

Islam MR, Gartoulla P, Bell RJ, Fradkin P, Davis SR. Prevalence of menopausal symptoms in Asian midlife women: a systematic review. Climacteric. 2015 abr.;18(2):157-76.

Sánchez J, Onatra W, Castellanos J, Sanjuanello C, Gamboa P, Ríos MT. Evaluación del riesgo cardiovascular y calidad de vida en mujeres pre y posmenopáusicas de la consulta de climaterio de tres hospitales de Bogotá. Periodo del 2011-2012. Rev Col Menopausia. 2013;19(4):280-91.

da Silva AR, d'Andretta Tanaka AC. Factors associated with menopausal symptom severity in middle-aged Brazilian women from the Brazilian Western Amazon. Maturitas. 2013 sept.;76(1):64-9.

Villaverde Gutiérrez C, Torres Luque G, Ábalos Medina GM, Argente del Castillo MJ, Guisado IM, Guisado Barrilao R, et al. Influence of exercise on mood in postmenopausal women. J Clin Nurs. 2012 abr.;21(7-8):923-8.

Wang L, Zhang R, Yang Y, Sun XY, Zhang BL, Zhu HY, et al. Severity and factors of menopausal symptoms in middle-aged women in Gansu Province of China: a cross-sectional study. BMC Womens Health. 2021 dic. 8;21(1):405.

Sabia S, Fournier A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Risk factors for onset of menopausal symptoms: results from a large cohort study. Maturitas. 2008 jun. 20;60(2):108-21.

Ford K, Sowers M, Crutchfield M, Wilson A, Jannausch M. A longitudinal study of the predictors of prevalence and severity of symptoms commonly associated with menopause. Menopause. 2005;12(3):308-17.

Li C, Samsioe G, Borgfeldt C, Lidfeldt J, Agardh CD, Nerbrand C. Menopause-related symptoms: what are the background factors? A prospective population-based cohort study of Swedish women (The Women's Health in Lund Area study). Am J Obstet Gynecol. 2003 dic.;189(6):1646-53.

Dušková M, Sim?nková K, Hill M, Velíková M, Kubátová J, Kancheva L, et al. Chronic cigarette smoking alters circulating sex hormones and neuroactive steroids in premenopausal women. Physiol Res. 2012;61(1):97-111.

Gu F, Caporaso NE, Schairer C, Fortner RT, Xu X, Hankinson SE, et al. Urinary concentrations of estrogens and estrogen metabolites and smoking in caucasian women. Cancer Epidemiol Biomarkers Prev. 2013 en.;22(1):58-68.

Gallicchio L, Miller SR, Visvanathan K, Lewis LM, Babus J, Zacur H, et al. Cigarette smoking, estrogen levels, and hot flashes in midlife women. Maturitas. 2006 en. 20;53(2):133-43.

Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015 abr.;175(4):531-9.

Freeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause. 2014 sept.;21(9):924-32.

David PS, Kling JM, Vegunta S, Faubion SS, Kapoor E, Mara KC, et al. Vasomotor symptoms in women over 60: results from the Data Registry on Experiences of Aging, Menopause, and Sexuality (DREAMS). Menopause. 2018 oct.;25(10):1105-9.

Espitia De La Hoz FJ. Prevalence of genitourinary syndrome of menopause and impact on sexuality of women in Quindío (Colombia), 2013-2016. Rev Colomb Obstet Ginecol. 2018;69(4):249-59.

Phillips NA, Bachmann GA. The genitourinary syndrome of menopause. Menopause. 2021 febr. 1;28(5):579-88.

Espitia De La Hoz FJ. Quality of life in women with genitourinary syndrome of menopause, in Quindío, Colombia. Rev Colomb Endocrinol Diabet Metab. 2023;10(1):e761.

Mitchell CM, Larson JC, Reed SD, Guthrie KA. The complexity of genitourinary syndrome of menopause: number, severity, and frequency of vulvovaginal discomfort symptoms in women enrolled in a randomized trial evaluating treatment for genitourinary syndrome of menopause. Menopause. 2023 ag. 1;30(8):791-7.

Pérez-López FR, Vieira-Baptista P, Phillips N, Cohen-Sacher B, Fialho SCAV, Stockdale CK. Clinical manifestations and evaluation of postmenopausal vulvovaginal atrophy. Gynecol Endocrinol. 2021 ag.;37(8):740-5.

Nik Hazlina NH, Norhayati MN, Shaiful Bahari I, Muhammad Arif NA. Prevalence of psychosomatic and genitourinary syndrome among menopausal women: a systematic review and meta-analysis. Front Med. 2022 mzo. 3;9:848202.

Nappi RE, Di Carlo C, Becorpi AM, Gambacciani M, De Seta F, Ribaldone R, et al. The effect of vulvovaginal atrophy on women's quality of life from an Italian cohort of the EVES study. J Obstet Gynaecol. 2020 my.;40(4):512-9.

Takahashi TA, Johnson KM. Menopause. Med Clin North Am. 2015 my.;99(3):521-34.

Minkin MJ. Menopause: hormones, lifestyle, and optimizing aging. Obstet Gynecol Clin North Am. 2019 sept.;46(3):501-14.

“The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022 jul. 1;29(7):767-94.

Mendoza N, Ramírez I, de la Viuda E, Coronado P, Baquedano L, Llaneza P, et al. Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group. Maturitas. 2022 dic.;166:65-85.

Voedisch AJ, Dunsmoor-Su R, Kasirsky J. Menopause: a global perspective and clinical guide for practice. Clin Obstet Gynecol. 2021 sept. 1;64(3):528-54.

Stuenkel CA, Santen RJ. An introduction to the Endocrine Society Clinical Practice Guideline on treatment of symptoms of the menopause. Post Reprod Health. 2016 mzo.;22(1):6-8.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2024 Revista Colombiana de Endocrinología, Diabetes & Metabolismo




Download data is not yet available.